Interpretable Machine Learning for Predicting Symptomatic Pneumonitis in Locally Advanced Non -Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Immune Checkpoint Inhibitor Consolidation

被引：0
|
作者：
Duan, L. [1 ]
Lee, S. H. [1 ]
Yegya-Raman, N. [1 ]
Wang, D. [1 ]
Li, B. [1 ]
Friedes, C. [1 ]
Iocolano, M. [1 ]
Kao, G. D. [1 ]
Fan, Y. [1 ]
Caruana, R. [2 ]
Feigenberg, S. J. [1 ]
Xiao, Y. [1 ]
机构：
[1] Univ Penn, Dept Radiat Oncol, Philadelphia, PA USA
[2] Microsoft Res, Redmond, WA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3010
引用
收藏
页码：E464 / E464
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER
    Almodovar, M.
    Ramos, H.
    Mota, P.
    Martins, V.
    Pereira, P.
    LUNG CANCER, 2011, 71 : S42 - S43
  • [22] IMPACT OF PRETRETMENT LEUKOCYTOSIS ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY
    Topkan, Erkan
    Parlak, Cem
    Guler, Ozan C.
    Pehlivan, Berrin
    Selek, Ugur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S412 - S412
  • [23] IMPACT OF PRETRETMENT LEUKOCYTOSIS ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY
    Topkan, Erkan
    Parlak, Cem
    Pehlivan, Berrin
    Ozyilkan, Ozgur
    Selek, Ugur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S556 - S556
  • [24] Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis
    Yang, Linlin
    Li, Butuo
    Xu, Yiyue
    Zou, Bing
    Fan, Bingjie
    Wang, Chunni
    Wang, Linlin
    FUTURE ONCOLOGY, 2023, 19 (16) : 1151 - 1160
  • [25] Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
    Thomas, Hannah M. T.
    Hippe, Daniel S.
    Forouzannezhad, Parisa
    Sasidharan, Balu Krishna
    Kinahan, Paul E.
    Miyaoka, Robert S.
    Vesselle, Hubert J.
    Rengan, Ramesh
    Zeng, Jing
    Bowen, Stephen R.
    DISCOVER ONCOLOGY, 2022, 13 (01)
  • [26] Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
    Hannah M. T. Thomas
    Daniel S. Hippe
    Parisa Forouzannezhad
    Balu Krishna Sasidharan
    Paul E. Kinahan
    Robert S. Miyaoka
    Hubert J. Vesselle
    Ramesh Rengan
    Jing Zeng
    Stephen R. Bowen
    Discover Oncology, 13
  • [27] A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer
    Zhang, Yao
    Zhang, Lincheng
    Cao, Shuhui
    Wang, Yue
    Ling, Xuxinyi
    Zhou, Yan
    Zhong, Hua
    CANCER MEDICINE, 2023, 12 (15): : 15998 - 16010
  • [28] Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy
    van Diessen, Judi N. A.
    Chen, Chun
    van den Heuvel, Michel M.
    Belderbos, Jose S. A.
    Sonke, Jan-Jakob
    RADIOTHERAPY AND ONCOLOGY, 2016, 118 (03) : 447 - 452
  • [29] Daily Step Counts Predict Outcomes for Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy
    Ohri, N.
    Halmos, B.
    Bodner, W. R., III
    Cheng, H.
    Guha, C.
    Kalnicki, S.
    Garg, M. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E524 - E525
  • [30] Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
    Katayama, H
    Ueoka, H
    Kiura, K
    Tabata, M
    Kozuki, T
    Tanimoto, M
    Fujiwara, T
    Tanaka, N
    Date, H
    Aoe, M
    Shimizu, N
    Takemoto, M
    Hiraki, Y
    BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 979 - 984
12345